Revealing Innate Immune Pathways to Build
ABOUT ONCHILLES PHARMA
Onchilles Pharma was founded on breakthrough research that was the first to describe that human neutrophils release a major anticancer protein, called ELANE, that broadly and selectively activates cell death pathways in cancer cells. This fundamental pathway of the innate immune system has the potential for universal anti-cancer activity, independent of genetic mutation. Based on this research, Onchilles is developing a pipeline of first-in-class biologic drug candidates with the potential to be broadly effective against a wide range of cancers.
NOVEL NEUTROPHIL PATHWAY BROADLY AND SELECTIVELY KILLS CANCER
Neutrophils are the most abundant white blood cell in the immune system, leading the innate immune system’s first line of defense against infections, inflammation, and cancer. New research by Onchilles’ scientific founder, Dr. Lev Becker, uncovered that neutrophils release neutrophil elastase (ELANE) which broadly and selectively activates a fundamental pathway in aberrant cancer cells to induce apoptosis. In animal models, the initiation by ELANE of this cancer cell killing pathway at the initial tumor site also resulted in increased adaptive immunity by T cells against distant metastases.
Onchilles is developing a pipeline of first-in-class biologic and small molecule drug candidates that have the potential to be broadly effective against a wide range of cancers. Initial in vitro and in vivo preclinical studies of the company’s first drug candidate to activate this pathway show direct and selective anti-cancer efficacy, an encouraging safety profile, and a lack of resistance with repeated exposure. Onchilles is advancing proof-of-concept preclinical studies for its lead drug candidate as well as exploring this novel pathway for additional drug targets.
IN THE NEWS
DISCOVER YOUR PATH
Onchilles Pharma is looking for talented and
enthusiastic people to join our quest.